26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Pulmonary Disease, Chronic ObstructiveCOPDLung Diseases, Obstructive
- Interventions
- Registration Number
- NCT00463567
- Lead Sponsor
- Novartis
- Brief Summary
Stage 1 of the study is designed to provide data about the risk-benefit of 4 dose regimens of indacaterol (75, 150, 300 \& 600 µg o.d.) in order to select two doses to carry forward into study Stage 2. Study Stage 2 will provide pivotal confirmation of efficacy, safety, and tolerability of the selected indacaterol doses in patients with COPD
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2059
-
Male and female adults aged ≥ 40 years, who have signed an Informed Consent Form prior to initiation of any study-related procedure
-
Co-operative outpatients with a diagnosis of COPD (moderate to severe as classified by the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) Guidelines, 2005) and:
- Smoking history of at least 20 pack years
- Post-bronchodilator FEV1 < 80% and ≥ 30% of the predicted normal value.
- Post-bronchodilator FEV1/FVC < 70% (Post refers to within 30 min of inhalation of 400 µg of salbutamol)
- Pregnant or lactating females
- Patients who have been hospitalized for a COPD exacerbation in the 6 weeks prior to Visit 1 or during the run-in period
- Patients requiring long term oxygen therapy (> 15 h a day)
- Patients who have had a respiratory tract infection 6 weeks prior to V1 (with further criteria)
- Patients with concomitant pulmonary disease, pulmonary tuberculosis, or clinically significant bronchiectasis
- Patients with a history of asthma (with further criteria)
- Patients with Type I or uncontrolled Type II diabetes
- Patients with contraindications for tiotropium
- Patients who have clinically relevant laboratory abnormalities or a clinically significant abnormality
- Any patient with active cancer or a history of cancer with less than 5 years disease free survival time
- Patients with a history of long QT syndrome or whose QTc interval is prolonged
- Patients with a hypersensitivity to any of the study drugs or drugs with similar chemical structures
- Patients who have had treatment with the investigational drug (with further criteria)
- Patients who have had live attenuated vaccinations within 30 days prior to visit 1, or during run-in period
- Patients with known history of non compliance to medication
- Patients unable to satisfactorily use a dry powder inhaler device or perform spirometry measurements
Other protocol-defined inclusion/exclusion criteria may apply
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Formoterol 12 µg (Not Continued Into Stage 2) Formoterol (12 µg b.i.d.) In the morning, Placebo to Indacaterol delivered via two SDDPI devices + Formoterol 12 µg delivered via Aerolizer. In evening, Formoterol 12 µg delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2. Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study. Indacaterol 75 µg (Not Continued into Stage 2) Placebo to Formoterol In the morning, Indacaterol 75 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2. Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study. Indacaterol 150 µg (Continued Into Stage 2) Placebo to Indacaterol In the morning, Indacaterol 150 µg once daily orally inhaled via a single dose dry powder inhaler (SDDPI) + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1. Daily Inhaled Corticosteroid (ICS) monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study. Indacaterol 150 µg (Continued Into Stage 2) Placebo to Formoterol In the morning, Indacaterol 150 µg once daily orally inhaled via a single dose dry powder inhaler (SDDPI) + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1. Daily Inhaled Corticosteroid (ICS) monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study. Indacaterol 300 µg (Continued Into Stage 2) Indacaterol In the morning, Indacaterol 300 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1. Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study. Indacaterol 150 µg (Continued Into Stage 2) Indacaterol In the morning, Indacaterol 150 µg once daily orally inhaled via a single dose dry powder inhaler (SDDPI) + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1. Daily Inhaled Corticosteroid (ICS) monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study. Indacaterol 300 µg (Continued Into Stage 2) Placebo to Indacaterol In the morning, Indacaterol 300 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1. Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study. Indacaterol 600 µg (Not Continued Into Stage 2) Indacaterol In the morning, 2 capsules of Indacaterol 300 µg once daily orally inhaled via two SDDPI devices + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2. Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study. Indacaterol 300 µg (Continued Into Stage 2) Placebo to Formoterol In the morning, Indacaterol 300 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1. Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study. Tiotropium 18 µg (Continued Into Stage 2) Tiotropium (18 µg o.d.) Tiotropium 18 µg dry powder capsules delivered (open label) via manufacturer's proprietary SDDPI, (Handihaler®). Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study. Indacaterol 600 µg (Not Continued Into Stage 2) Placebo to Formoterol In the morning, 2 capsules of Indacaterol 300 µg once daily orally inhaled via two SDDPI devices + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2. Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study. Placebo (Continued Into Stage 2) Placebo to Indacaterol In the morning, Placebo to Indacaterol delivered via two SDDPI devices + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1. Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study. Placebo (Continued Into Stage 2) Placebo to Formoterol In the morning, Placebo to Indacaterol delivered via two SDDPI devices + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1. Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study. Indacaterol 75 µg (Not Continued into Stage 2) Placebo to Indacaterol In the morning, Indacaterol 75 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2. Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study. Formoterol 12 µg (Not Continued Into Stage 2) Placebo to Indacaterol In the morning, Placebo to Indacaterol delivered via two SDDPI devices + Formoterol 12 µg delivered via Aerolizer. In evening, Formoterol 12 µg delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2. Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study. Indacaterol 75 µg (Not Continued into Stage 2) Indacaterol In the morning, Indacaterol 75 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2. Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.
- Primary Outcome Measures
Name Time Method Trough Forced Expiratory Volume in 1 Second (FEV1) Assessed by Spirometry 24 Hour Post Dose After 12 Weeks of Treatment after 12 weeks of treatment FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of the 23 h 10 min and the 23 h 45 min post dose values. Mixed model used baseline FEV1, FEV1 prior to and 30 minutes post inhalation of salbutamol/albuterol, and FEV1 prior to and 1 hour post inhalation of ipratropium as covariates.
- Secondary Outcome Measures
Name Time Method The Percentage of "Days of Poor Control" Reported Over the 26 Week Treatment Period up to 26 weeks A Chronic Obstructive Pulmonary Disease (COPD) "day of poor control" was defined as any day in the participant's diary with a score ≥2 (moderate or severe) for at least 2 of 5 symptoms (cough, wheeze, production of sputum, color of sputum, breathlessness). Score for each symptom ranges from 0-3; a higher number indicates a more severe symptom. The model contained baseline percentage of "days of poor control" as well as FEV1 reversibility components as covariates.
Trial Locations
- Locations (193)
Asthma & Allergy Research Associates
🇺🇸Dallas, Texas, United States
North Shore University Hospital
🇺🇸New Hyde Park, New York, United States
University of North Carolina
🇺🇸Chapel Hill, North Carolina, United States
Neutrotrials Research Inc
🇺🇸Atlanta, Georgia, United States
Ohio State University - Davis Heart and Lung Research Institute
🇺🇸Columbus, Ohio, United States
Remington-Davis Clinical Research
🇺🇸Columbus, Ohio, United States
South Hills Pulmonary Associates
🇺🇸Pittsburgh, Pennsylvania, United States
University Hospitals of Cleveland
🇺🇸Cleveland, Ohio, United States
Metro Health Medical Center
🇺🇸Cleveland, Ohio, United States
Cleveland Clinic
🇺🇸Cleveland, Ohio, United States
University of Miami School of Medicine
🇺🇸Miami, Florida, United States
Elite Research Institute
🇺🇸Miami, Florida, United States
*Private Practice*
🇺🇸Houston, Texas, United States
Houstons Veteran's Medical Center
🇺🇸Houston, Texas, United States
Clinical Research Center of NV
🇺🇸Las Vegas, Nevada, United States
Community Research Inc
🇺🇸Cincinnati, Ohio, United States
Cincinnati VA Hospital
🇺🇸Cincinnati, Ohio, United States
New Horizons Clinical Research
🇺🇸Cincinnati, Ohio, United States
Bernstein Clinical Research Centre
🇺🇸Cincinnati, Ohio, United States
Quality Assurance Research Centre
🇺🇸San Antonio, Texas, United States
Audie L. Murphy VA Hospital
🇺🇸San Antonio, Texas, United States
Diagnostics Research Group
🇺🇸San Antonio, Texas, United States
Heart of America Research Institute
🇺🇸Shawnee Mission, Kansas, United States
Cotton-O'Neil Clinical Research Center
🇺🇸Topeka, Kansas, United States
National Jewish Medical & Research Center
🇺🇸Denver, Colorado, United States
Harper University Hospital; Wayne State University
🇺🇸Detroit, Michigan, United States
Mayo Clinic
🇺🇸Rochester, Minnesota, United States
Oklahoma Allergy and Asthma Clinic
🇺🇸Oklahoma City, Oklahoma, United States
University of Oklahoma Health Science Center
🇺🇸Oklahoma City, Oklahoma, United States
Lynne Health Science Institute
🇺🇸Oklahoma City, Oklahoma, United States
Allergy Associates Research Center
🇺🇸Portland, Oregon, United States
Dickson Family Medicine Group, PC
🇺🇸Nashville, Tennessee, United States
Omaha VA Medical Center
🇺🇸Omaha, Nebraska, United States
Quality Clinical Research
🇺🇸Omaha, Nebraska, United States
Creighton University Centre for Allergy, Asthma & Immunology
🇺🇸Omaha, Nebraska, United States
Creigton University
🇺🇸Omaha, Nebraska, United States
Midwest Allergy and Asthma Clinic
🇺🇸Omaha, Nebraska, United States
Heartland Clinical Research, Inc
🇺🇸Omaha, Nebraska, United States
Meridian Clinical Research, LLC
🇺🇸Omaha, Nebraska, United States
University of Nebraska Medical Center - Pulmonary Research
🇺🇸Omaha, Nebraska, United States
Weill Medical College of Cornell University
🇺🇸New York, New York, United States
New York Pulmonary Associates, PC
🇺🇸New York, New York, United States
Allergy and Asthma Research Center, PA
🇺🇸San Antonio, Texas, United States
Wellmed Clinical Research
🇺🇸San Antonio, Texas, United States
West Houston Allergy and Asthma, PA
🇺🇸Katy, Texas, United States
University of Chicago Hospital
🇺🇸Chicago, Illinois, United States
Southern California Institute for Respiratory Diseases
🇺🇸Los Angeles, California, United States
Interlink Research Institute
🇺🇸Los Alamitos, California, United States
Encompass Clinical Research
🇺🇸Spring Valley, California, United States
California Allergy & Asthma Medical Group
🇺🇸Palmdale, California, United States
Pulmonary Medicine Associates PC
🇺🇸Homewood, Alabama, United States
SAVAHSC / Pulmonary Section
🇺🇸Tucson, Arizona, United States
Pulmonary Associate of Mobile, PC
🇺🇸Mobile, Alabama, United States
Jasper Summit Research
🇺🇸Jasper, Alabama, United States
University of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States
Pinnacle Research Group, LLC
🇺🇸Anniston, Alabama, United States
California Research
🇺🇸Fullerton, California, United States
Canyon Clinical Research, LLC
🇺🇸Tucson, Arizona, United States
USC Rancho Amigos Medical Center
🇺🇸Downey, California, United States
Bensch Clinical Research Associates
🇺🇸Stockton, California, United States
David Geffen UCLA School of Medicine
🇺🇸Los Angeles, California, United States
Allergy & Asthma Associates of Santa Clara Res. Center
🇺🇸San Jose, California, United States
Boulder Medical Center
🇺🇸Boulder, Colorado, United States
Peninsula Pulmonary Medical Associates
🇺🇸Torrance, California, United States
Intergrated Research Group
🇺🇸Riverside, California, United States
University of South Florida
🇺🇸Tampa, Florida, United States
Sneeze, Wheeze & Itch Associates, LLC
🇺🇸Normal, Illinois, United States
New Orleans Center for Clinical Research
🇺🇸New Orleans, Louisiana, United States
Rx R&D
🇺🇸Metaire, Louisiana, United States
Primecare Physician Associates
🇺🇸Biddeford, Maine, United States
Miray Medical Center
🇺🇸Brockton, Massachusetts, United States
ClinSite, Inc
🇺🇸Ann Arbor, Michigan, United States
Minnesota Lung Center
🇺🇸Minneapolis, Minnesota, United States
Pulmonary Respiratory Institute of Southwest Michigan
🇺🇸Livonia, Michigan, United States
St. Luke's Cardio-Pulmonary Research
🇺🇸Chesterfield, Missouri, United States
Synergy Medical Education Alliance
🇺🇸Saginaw, Michigan, United States
Kansas City University of Medicine and Biosciences
🇺🇸Kansas City, Missouri, United States
Crescent Medical Associates
🇺🇸Astoria, New York, United States
Pulmonary and Critical Care Services
🇺🇸Albany, New York, United States
The Asthma & Allergy Center, PC
🇺🇸Papillion, Nebraska, United States
Asthma and Allergy Associates
🇺🇸Elmira, New York, United States
Tri-State Medical Group
🇺🇸Beaver, Pennsylvania, United States
Med Plus South - Strand Family Practice
🇺🇸Garden City, South Carolina, United States
Chest Diseases of Northwestern PA
🇺🇸Erie, Pennsylvania, United States
New England Center for Clinical Research
🇺🇸Cranston, Rhode Island, United States
Clinical Research Institute of Southern Oregon, PC
🇺🇸Medford, Oregon, United States
Texas Pulmonary & Critical Care
🇺🇸Ft. Worth, Texas, United States
Medical University of South Carolina
🇺🇸Charleston, South Carolina, United States
Heartland Medical, P.C
🇺🇸New Tazewell, Tennessee, United States
University of Texas Medical Branch at Galveston
🇺🇸Galveston, Texas, United States
PharmaTex Research LLC
🇺🇸Amarillo, Texas, United States
Baylor College of Medicine
🇺🇸Houston, Texas, United States
Volunteer Research Center
🇺🇸Knoxville, Tennessee, United States
Drexel University College of Medicine
🇺🇸Philadelphia, Pennsylvania, United States
The University of Toledo
🇺🇸Toledo, Ohio, United States
Low County Lung and Critical Care, PA
🇺🇸Charleston, South Carolina, United States
Hugh D. Durrence, MD, Family Medicine
🇺🇸Charleston, South Carolina, United States
MultiSpeciality Clinical Research
🇺🇸Johnson City, Tennessee, United States
Western Sky Medical Research
🇺🇸El Paso, Texas, United States
Central Texas Health Research
🇺🇸New Braunfels, Texas, United States
Pulmonary and Research Associates
🇺🇸Spokane, Washington, United States
Pulmonary Consultants, PLLC
🇺🇸Tacoma, Washington, United States
Partners in Clinical Research
🇺🇸Cumberland, Rhode Island, United States
Johnston Memorial Hospital Pulmonary Research
🇺🇸Abingdon, Virginia, United States
Novartis
🇹🇷Istanbul, Turkey
University of Virginia
🇺🇸Charlottesville, Virginia, United States
Lynchburg Pulmonary Associates
🇺🇸Lynchburg, Virginia, United States
Vermont Lung Center
🇺🇸Colchester, Vermont, United States
Charleston Area Medical Center
🇺🇸Charleston, West Virginia, United States
Pharmaceutical Research & Consulting, Inc
🇺🇸Dallas, Texas, United States
Trinity Clinic - Corsicana
🇺🇸Corsicana, Texas, United States
Holston Medical Group
🇺🇸Kingsport, Tennessee, United States
Merit Care Medical Group
🇺🇸Fargo, North Dakota, United States
North Carolina Clinical Research
🇺🇸Raleigh, North Carolina, United States
William L. Gray Research
🇺🇸Spokane, Washington, United States
Madigan Army medical Center / Dept. of Army
🇺🇸Tacoma, Washington, United States
Dawes Fretzin Clinical Research Group LLC
🇺🇸Indianapolis, Indiana, United States
Clinical Research Institute
🇺🇸Minneapolis, Minnesota, United States
Novartis Investigative Center
🇺🇸Scottsdale, Arizona, United States
Fallon Clinic at Worcester Medical Center
🇺🇸Worcester, Massachusetts, United States
Allergy Research Foundation, Inc
🇺🇸Los Angeles, California, United States
Pulmonary Associates, PA
🇺🇸Phoenix, Arizona, United States
Novartis Investigator Site
🇹🇷Yenisehir, Turkey
Progressive Clinical Research
🇺🇸Vista, California, United States
Greater Los Angeles Healthcare System
🇺🇸Sepulveda, California, United States
Advance Clinical Research Institute
🇺🇸Orange, California, United States
Northern Colorado Pulmonary Consultants, PC
🇺🇸Fort Collins, Colorado, United States
New West Physicians Clinical research
🇺🇸Golden, Colorado, United States
Allergy and Asthma Clinical Research Inc
🇺🇸Walnut Creek, California, United States
Rocky Mountain Center for Clinical Research
🇺🇸Wheat Ridge, Colorado, United States
Lung Health & Sleep Enhancement Center
🇺🇸Newark, Delaware, United States
Western States Clinical Research
🇺🇸Wheat Ridge, Colorado, United States
Clinical Research of West Florida
🇺🇸Clearwater, Florida, United States
University of Florida Shands Hospital
🇺🇸Gainesville, Florida, United States
Innovative Research of West Florida
🇺🇸Largo, Florida, United States
Shands Jacksonville Medical Center
🇺🇸Jacksonville, Florida, United States
Pensacola Research Consultants
🇺🇸Pensacola, Florida, United States
Emerald Coast Clinical Research, LLC
🇺🇸Pensacola, Florida, United States
Integrity Research
🇺🇸Pensacola, Florida, United States
Brevard Pulmonary Specialists
🇺🇸Rockledge, Florida, United States
Asthma & Allergy Research Center
🇺🇸Sarasota, Florida, United States
South Miami Clinical Research, LLC
🇺🇸South Miami, Florida, United States
Central Medical Group, PA
🇺🇸Tamarac, Florida, United States
Clireco, Inc
🇺🇸Tamarac, Florida, United States
Marietta Pulmonary Medicine
🇺🇸Marietta, Georgia, United States
Georgia Clinical Research
🇺🇸Austell, Georgia, United States
Community Hospital Anderson
🇺🇸Anderson, Indiana, United States
Iowa Clinical Research Corporation
🇺🇸Iowa City, Iowa, United States
University of Iowa
🇺🇸Iowa City, Iowa, United States
Southern Illinois Clinical Research Center
🇺🇸O'Fallon, Illinois, United States
South Bend Clinic
🇺🇸South Bend, Indiana, United States
University of Kentucky Chandler Medical Center
🇺🇸Lexington, Kentucky, United States
Kentucky Medical research Center
🇺🇸Lexington, Kentucky, United States
Family Asthma and Allergy Research Associates
🇺🇸Louisville, Kentucky, United States
Gulf Coast Research, LLC
🇺🇸Lafayette, Louisiana, United States
Louisiana Health Sciences Center
🇺🇸Shreveport, Louisiana, United States
Northshore Research Associates
🇺🇸Slidell, Louisiana, United States
Allergy, Asthma, Immunology, Pharmaceutical Studies
🇺🇸Bangor, Maine, United States
John Hopkins Asthma and Allergy Center
🇺🇸Baltimore, Maryland, United States
University of Missouri - Columbia
🇺🇸Columbia, Missouri, United States
The Clinical Research Centre
🇺🇸St, Louis, Missouri, United States
University of Missouri KC/ Truman Medical
🇺🇸Kansas City, Missouri, United States
Midwest Chest Consultants
🇺🇸St. Charles, Missouri, United States
Washington U School of Medicine, Center for Clinical Studies
🇺🇸St. Louis, Missouri, United States
Somnos Laboratories, Inc
🇺🇸Lincoln, Nebraska, United States
Montana Health Research Institute
🇺🇸Billings, Montana, United States
Lovelace Scientific Resources, Inc.
🇺🇸Henderson, Nevada, United States
Pulmonary and Allergy Associates, PA
🇺🇸Summit, New Jersey, United States
Delaware Valley Clinical Research
🇺🇸Cherry Hill, New Jersey, United States
Dartmouth Hitchcock Medical Center
🇺🇸Lebanon, New Hampshire, United States
Pulmonary and Critical Care Associates, PA
🇺🇸East Brunswick, New Jersey, United States
AAIR research Centre
🇺🇸Rochester, New York, United States
Mount Sinai Medical Center
🇺🇸New York, New York, United States
Nassau Chest Physicians, PC
🇺🇸Massapequa, New York, United States
Sensenbrenner Primary Care
🇺🇸Charlotte, North Carolina, United States
Cloverdale Research Facility
🇺🇸Winston Salem, North Carolina, United States
Advanced Health Care Specialists
🇺🇸Thornville, Ohio, United States
Pharmacotherapy Research Associates, Inc
🇺🇸Zanesville, Ohio, United States
John Winder Associates
🇺🇸Sylvania, Ohio, United States
Healthcare Research Consultants, Inc
🇺🇸Tulsa, Oklahoma, United States
River Road Medical Group
🇺🇸Eugene, Oregon, United States
Oregon Clinical Research Associates
🇺🇸Medford, Oregon, United States
Asthma Allergy &Pulmonary Associates, PC
🇺🇸Philadelphia, Pennsylvania, United States
Pittsburgh Pulmonary Associates
🇺🇸Pittsburgh, Pennsylvania, United States
Palmetto Pulmonary Medicine, PA - Sleep Disorders Lab
🇺🇸Varnville, South Carolina, United States
Spartanburg Pharmaceutical Research
🇺🇸Spartanburg, South Carolina, United States
Norwalk Hospital
🇺🇸Norwalk, Connecticut, United States
Premiere Pharmaceutical Research, LLC
🇺🇸Tempe, Arizona, United States
LSU Health Sciences Center/LSU School of Medicine
🇺🇸New Orleans, Louisiana, United States
Arizona Pulmonary Specialists, LTD
🇺🇸Scottsdale, Arizona, United States
Encompass Clinical Research - North Coast
🇺🇸Encinitas, California, United States
Allergy and Asthma Specialists Medical Group and research Center
🇺🇸Huntington Beach, California, United States
Madrona Medical Group - Clinical Research Dept.
🇺🇸Bellingham, Washington, United States